Corbus Pharmaceuticals said the final participant in its 240-patient CANYON-1 Phase 1b study of CRB-913 has completed their last clinical visit, and that topline results remain scheduled for September 2026.
CRB-913 is an oral, once-daily CB1 inverse agonist \u2014 a drug designed to block a receptor involved in appetite regulation \u2014 that the company describes as highly peripherally restricted, meaning it is intended to act largely outside the brain. Corbus positions it as an alternative to GLP-1 and other incretin-based weight-loss drugs.
CANYON-1 ran for 16 weeks at multiple U.S. sites in obese, non-diabetic adults. Participants were randomised 1:1:1:1 across three dose groups \u2014 20 mg, 40 mg and 60 mg once daily \u2014 and placebo. All treated participants started at 20 mg and titrated upward depending on cohort assignment. Dosing ran 12 weeks, followed by a four-week safety follow-up. The study is registered as NCT07310901.
The announcement contains no efficacy or safety data from CANYON-1. Completion of the last patient visit is an operational milestone; it says nothing about the outcome, which will only become clear at the September readout.
The earlier Phase 1a study, finished in December 2025, tested single and multiple ascending doses. The single-dose portion enrolled 64 participants across eight cohorts, up to 600 mg per day. The multiple-dose portion enrolled 48 participants across four cohorts, up to 150 mg per day, including a dedicated obese cohort.
In that obese cohort at 150 mg per day, Corbus reported that all nine treated participants lost weight while none of the three on placebo did, with a mean 2.9% placebo-adjusted weight loss by day 14. Those numbers come from a very small group over a short period, and the company's own dose range in CANYON-1 tops out at 60 mg \u2014 well below the 150 mg used in the Phase 1a obese cohort.
Corbus also said the Phase 1a trial produced no reports of vomiting, constipation or nausea, and that daily neuropsychiatric screening using the CSSRS, PHQ-9 and GAD-7 instruments was negative. Neuropsychiatric side effects are the historical concern for CB1-targeting weight-loss drugs; the company states CRB-913 showed 15 times lower brain penetration than monlunabant in mice, an animal-model comparison rather than a human one.
Chief Executive Yuval Cohen said the readout should "allow us to contextualize the data in comparison to both oral GLP-1 agonists as well as the CB1 inverse agonist monlunabant." He also cited discontinuation rates above 60% in the first year among patients starting incretin therapy as the gap the drug is meant to address.
Corbus, based in Norwood, Massachusetts, is also developing CRB-701, an antibody-drug conjugate targeting Nectin-4-expressing tumours. The release does not disclose the company's cash position or expected runway through the CANYON-1 readout.
Source: GlobeNewswire
This article is journalism, not investment advice. It is not an offer or solicitation to buy or sell any security. Micro-cap and penny stocks carry a high risk of loss, including illiquidity and dilution. Do your own research.